Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans

Chun Li, Mita Kuchimanchi, Dean Hickman, Leszek Poppe, Mike Hayashi, Yihong Zhou, Raju Subramanian, Gondi Kumar and Sekhar Surapaneni
Drug Metabolism and Disposition July 2009, 37 (7) 1378-1394; DOI: https://doi.org/10.1124/dmd.108.025742
Chun Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mita Kuchimanchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Hickman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leszek Poppe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Hayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yihong Zhou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raju Subramanian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gondi Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sekhar Surapaneni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Motesanib diphosphate is a novel, investigational, highly selective oral inhibitor of the receptor tyrosine kinases vascular endothelial growth factor receptors 1, 2, and 3, the platelet-derived growth factor receptor, and the stem cell factor receptor (Kit). The in vitro metabolic profiles of [14C]motesanib were examined by using microsomes and hepatocytes from preclinical species and humans. Several oxidative metabolites were observed and characterized by tandem mass spectrometry, nuclear magnetic resonance spectroscopy, and coinjection with authentic standards. Cytochrome P450 (P450) 3A4 is the major isozyme involved in the oxidative biotransformation of motesanib, but the CYP2D6 and CYP1A isozymes also make minor contributions. In hepatocyte incubations, oxidative and conjugative pathways were observed for all species examined, and indoline N-glucuronidation was the dominant pathway. Three less common and novel phase II conjugates of the indoline nitrogen were detected in hepatocytes and in microsomes supplemented with specific cofactors, including N-carbamoyl glucuronide, N-glucose, and N-linked β-N-acetylglucosamine. An N-glucuronide metabolite was the most frequently observed phase II conjugate in liver microsomes of all species, whereas the N-acetylglucosamine conjugate was observed only in monkey liver microsomes. Incubations with recombinant human UDP-glucuronosyltransferases (UGTs) and inhibition by the UGT1A4 and UGT1A1 substrates/inhibitors imipramine and bilirubin suggested that UGT1A4 is the major UGT isozyme catalyzing the N-glucuronidation of motesanib, with a minor contribution from UGT1A1. The in vitro metabolic profiles were similar between the human and preclinical species examined. All metabolites found in humans were also detected in other species.

Footnotes

  • This work was funded by Amgen Inc. (Thousand Oaks, CA).

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.108.025742.

  • ABBREVIATIONS: VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; Kit, stem cell factor receptor; P450, cytochrome P450; UGT, UDP-glucuronosyltransferase; M3, oxidative metabolite of motesanib, pyridine N-oxide; M4, oxidative metabolite of motesanib, lactam (oxindole); M1, conjugative metabolite of motesanib, indoline N-glucuronide; HPLC, high-pressure liquid chromatography; DAD, diode array detector; GA, glucuronic acid; HLM, human liver microsome; M5, oxidative metabolite of motesanib, carbinolamine; Ma, conjugative metabolite of motesanib, indoline N-carbamoyl glucuronide; LC/MS/MS, liquid chromatography/tandem mass spectrometry; ESI, electrospray ionization; LC/MS, LC/mass spectrometry; Mx, oxidative N-dealkylated metabolite of motesanib, isonicotinic acid; Q-TOF, quadrupole time-of-flight; 1D, one dimensional; 2D, two dimensional; HMBC, heteronuclear multiple bond correlation; Mb, conjugative metabolite of motesanib, indoline N-glucose; Mc, conjugative metabolite of motesanib, indoline N-N-acetylglucosamine; M2, oxidative metabolite of motesanib, structure unassigned; Miv, oxidative N-dealkylated metabolite of motesanib, lactam of Mv; Mv, oxidative N-dealkylated metabolite of motesanib, 2-amino nicotinamide; CID, collision-induced dissociation; ILT-threo, l-threo isoleucine thiazolidide [(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3 yl)-pentan-2-amine fumarate (2:1)].

  • ↵1 Current affiliation: Pharmacokinetics and Drug Metabolism, Pharmacology Department, Genomics Institute of the Novartis Research Foundation, San Diego, California.

  • ↵2 Drug Metabolism and Pharmacokinetics, Early Drug Development, Celgene Corporation, Summit, New Jersey.

    • Accepted April 13, 2009.
    • Received November 19, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 37 (7)
Drug Metabolism and Disposition
Vol. 37, Issue 7
1 Jul 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans

Chun Li, Mita Kuchimanchi, Dean Hickman, Leszek Poppe, Mike Hayashi, Yihong Zhou, Raju Subramanian, Gondi Kumar and Sekhar Surapaneni
Drug Metabolism and Disposition July 1, 2009, 37 (7) 1378-1394; DOI: https://doi.org/10.1124/dmd.108.025742

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans

Chun Li, Mita Kuchimanchi, Dean Hickman, Leszek Poppe, Mike Hayashi, Yihong Zhou, Raju Subramanian, Gondi Kumar and Sekhar Surapaneni
Drug Metabolism and Disposition July 1, 2009, 37 (7) 1378-1394; DOI: https://doi.org/10.1124/dmd.108.025742
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics